Abstract
The development of primary or acquired taxane resistance inevitably becomes to be the main problem. Ixabepilone is effective in metastatic breast cancer (MBC) patients including those heavily pretreated or resistant to taxanes. Eribulin has been used for the treatment of MBC patients who have received at least two prior chemotherapy regimens. New microtubule-targeting agents are promising to be effective options for patients progressing after standard taxane-containing chemotherapy. Key words: Breast neoplasms; Taxoids; Drug resistance; Microtubules
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
